Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Efficacy and safety of cetuximab+irinotecan for unresectable advanced or recurrent colorectal cancer].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 May 2013

Soda Hitoshi, Nemoto Hiroshi, Akatsuka Sotaro, Arioka Hitoshi, Shimada Ken, Ito Tomohiro, Takinishi Yasutaka, Egawa Mizutomo, Nagashima Atsushi, Kenmochi Takeshi, Sasaki Toru, Azuma Tomoaki, Koizumi Wasaburo, Hibi Kenji

Abstract excerpt

BACKGROUND: In July 2008, cetuximab treatment for unresectable advanced or recurrent colorectal cancer was approved in Japan, but there have been few reports on this therapy in Japan. PURPOSE: We retrospectively analyzed the efficacy and safety of cetuximab(Cmab)+irinotecan(CPT-11)for unresectable advanced or recurrent colorectal cancer from October 2008 to April 2010 at 5 centers in the Kanagawa region. PATIENTS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Cetuximab

Share to Irinotecan

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Recurrence

Source

Identifiers

PMID: 23863582

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Efficacy and safety of cetuximab+irinotecan for unresectable advanced or recurrent colorectal cancer].PMID 23863582Read ↗

[Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].Semantic proximity Read ↗

A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.Semantic proximity Read ↗

Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.Semantic proximity Read ↗

Radiotherapy Combined with Raltitrexed and Irinotecan for Treating Unresectable Recurrent Colorectal CancerSemantic proximity Read ↗

Alternating Oxaliplatin and Irinotecan Chemotherapy Combined With Capecitabine and Bevacizumab for Microsatellite-stable Stage IV Metastatic Colon Cancer With a BRAF V600E Mutation: Two Case Reports Indicating Survival Improvement over Standard Therapy.Semantic proximity Read ↗

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.Semantic proximity Read ↗

[Two Cases of Recurrent Colon Cancer with BRAF Mutation].Semantic proximity Read ↗

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.Semantic proximity Read ↗

[Analysis of therapeutic effect and prognosis in patients with metastatic colorectal cancer and different K-ras status].Semantic proximity Read ↗

Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.Semantic proximity Read ↗

Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A Pilot Study.Semantic proximity Read ↗

[Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.